Forekomsten af hjertesvigt ved kombination med insulin (rosiglitazon gives for at understøtte insulinbehandling) var 2, 4% sammenlignet med 1, 1% for insulin givet alene.
The incidence of heart failure in combination with insulin (rosiglitazone added to established insulin therapy) was 2.4%, compared to insulin alone, 1.1%.